This page shows the latest Sprycel news and features for those working in and with pharma, biotech and healthcare.
and leukaemia drug Sprycel (dasatinib) which brought in $558m, also up 14%.
There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy
Overturning its former ruling against the oral therapy, NICE recommended Sprycel in final guidance for first- and second-line treatment of adults with CML. ... BMS has now agreed a patient access scheme for Sprycel, which brought in sales of $472m this
BMS' other growth products also contributed to the sales gains, with melanoma drug Yervoy (ipilimumab) rising 19% to $285m and Sprycel (dasatinib) for leukaemia up 15% to $472m.
Bristol-Myers Squibb. Sprycel (dasatinib). Chronic myeloid leukaemia. Eisai. Halaven (eribulin). Breast cancer.
Company. Drug. Indication. Bayer. Stivarga (regorafenib). Sarcoma. Bristol-Myers Squibb. Sprycel (dasatinib).
More from news
Approximately 4 fully matching, plus 26 partially matching documents found.
recommended for use in patients who have grown resistance to Tasigna (nilotinib) and Gleevec/Glivec (imatinib mesylate) from Novartis and Bristol-Myers Squibb's Sprycel (dasatinib). ... The drug was then developed with the specific intention of
of the compulsory licence process for Herceptin, Sprycel and Ixempra, revocation of a patent for Pfizer's Sutent and a legal ruling allowing a generic version of Tarceva.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...